
Gilead Sciences, Inc. (NASDAQ:GILD) reported first-quarter revenue growth of 3% year-over-year to $6.59 billion, beating the consensus of $6.28 billion.
The increase is attributed to demand for Biktarvy® and Veklury®, partially offset by the loss of exclusivity for Truvada® in the United States and unfavorable pricing dynamics for hepatitis C virus products.